Crossmark

Cerebrospinal fluid can exit into the skull bone marrow and instruct cranial hematopoiesis in mice with bacterial meningitis

Crossref DOI link: https://doi.org/10.1038/s41593-022-01060-2

Published Online: 2022-05-02

Published Print: 2022-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pulous, Fadi E. https://orcid.org/0000-0002-0794-8078
Cruz-Hernández, Jean C.

Yang, Chongbo

Kaya, Ζeynep

Paccalet, Alexandre https://orcid.org/0000-0002-6331-562X
Wojtkiewicz, Gregory https://orcid.org/0000-0002-3148-8411
Capen, Diane

Brown, Dennis

Wu, Juwell W.

Schloss, Maximilian J.

Vinegoni, Claudio https://orcid.org/0000-0002-9818-3639
Richter, Dmitry

Yamazoe, Masahiro

Hulsmans, Maarten https://orcid.org/0000-0003-1009-658X
Momin, Noor

Grune, Jana

Rohde, David https://orcid.org/0000-0002-3785-9375
McAlpine, Cameron S.

Panizzi, Peter

Weissleder, Ralph

Kim, Dong-Eog

Swirski, Filip K. https://orcid.org/0000-0002-3163-9152
Lin, Charles P. https://orcid.org/0000-0002-7450-627X
Moskowitz, Michael A. https://orcid.org/0000-0002-9052-4937
Nahrendorf, Matthias https://orcid.org/0000-0002-4021-1887
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS108419)
License Information

Text and Data Mining valid from 2022-05-01

Version of Record valid from 2022-05-01
More Information

Article History

Received: 19 October 2021

Accepted: 23 March 2022

First Online: 2 May 2022

Competing interests

: M.N. has received funds or material research support from Lilly, Alnylam, Biotronik, CSL Behring, GlycoMimetics, GSK, Medtronic, Novartis and Pfizer, as well as consulting fees from Biogen, Gimv, IFM Therapeutics, Molecular Imaging, Sigilon, NovoNordisk and Verseau Therapeutics. The other authors declare no competing interests.

Document is current

Any future updates will be listed below